摘要
目的探讨氨溴索联合布地奈德福莫特罗治疗重度慢性阻塞性肺疾病(简称慢阻肺)合并肥胖型阻塞性睡眠呼吸暂停低通气综合征(obstructive sleep apnea hypopnea syndrome,OSAHS)的疗效。方法选取2018年1月至2020年1月确山县人民医院呼吸科63例重度慢阻肺合并肥胖型OSAHS患者作为研究对象,随机分为研究组(32例)与对照组(31例),对照组给予布地奈德福莫特罗,研究组联用氨溴索,均治疗14 d。对比两组治疗前后D-二聚体(D-Dimer,D-D)、C反应蛋白(C-reactive protein,CRP)、可溶性白细胞介素-2受体(soluble interleukin-2 receptor,SIL-2R)、第1秒用力呼气量(forced expiratory volume in 1 second,FEV1)、用力肺活量(forced vital capacity,FVC)、最大呼气中段流量(maximum mid expiratory flow,MMEF_(25~75))、FEV1/FVC比值及不良反应。结果两组治疗前D-D、CRP、SIL-2R、FEV1、MMEF_(25~75)、FEV1/FVC差异无统计学意义(P>0.05),治疗后研究组D-D、CRP、SIL-2R低于对照组,FEV1、MMEF_(25~75)、FEV1/FVC高于对照组,差异有统计学意义(P<0.05)。两组总不良反应率差异无统计学意义(P>0.05)。结论氨溴索联合布地奈德福莫特罗可有效改善重度慢阻肺合并肥胖型OSAHS患者肺功能及气道炎症,且安全性较高。
Objective To investigate the efficacy of ambroxol combined with budesonide and formoterol in the treatment of severe chronic obstructive pulmonary disease(COPD)complicated with obese obstructive sleep apnea hypopnea syndrome(OSAHS).Methods A total of 63 patients with severe COPD complicated with obese OSAHS were randomly divided into study group(32 cases)and control group(31 cases).The control group was treated with budesonide and formoterol for 14 days,while the study group was treated with ambroxol based on the treatment of budesonide and formoterol.D-Dimer(D-D),C-reactive protein(CRP),soluble interleukin-2 receptor(SIL-2 R),forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),maximum mid expiratory flow(MMEF_(25-75)),FEV1/FVC ratio and adverse reactions were compared between the two groups before and after treatment.Results There was no significant difference in D-D,CRP,SIL-2 R,FEV1,MMEF_(25-75)and FEV1/FVC between the two groups before treatment(P>0.05).After treatment,D-D,CRP and SIL-2 R in the study group were lower than those in the control group(P<0.05),while FEV1,MMEF_(25-75)and FEV1/FVC in the study group were higher than those in the control group(P<0.05).There was no significant difference in the total adverse reaction rate between the two groups(P>0.05).Conclusion Ambroxol combined with budesonide and formoterol can effectively improve pulmonary function and airway inflammation in patients with severe COPD complicated with obese OSAHS,and it has high safety.
作者
朱来成
ZHU Lai-cheng(Emergency Department,Queshan People’s Hospital,Zhumadian,Henan 463200,China)
出处
《慢性病学杂志》
2021年第9期1317-1320,共4页
Chronic Pathematology Journal
